Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Rakesh Jain, Dalei Chen, John Edwards & Maju Mathews. (2014) Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials. Current Medical Research and Opinion 30:2, pages 263-270.
Read now
Read now
Richard Weisler, Roger S McIntyre & Michael Bauer. (2013) Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy. Expert Review of Neurotherapeutics 13:11, pages 1183-1200.
Read now
Read now
Stuart Montgomery & Mike Briley. (2011) Noradrenergic symptom cluster in depression. Neuropsychiatric Disease and Treatment 7:sup1, pages 1-2.
Read now
Read now
Mazen K Ali & Raymond W Lam. (2011) Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment 7, pages 39-49.
Read now
Read now
Michele Fornaro, Eugenio Aguglia, Liliana Dell'Osso & Giulio Perugi. (2011) Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?. Expert Opinion on Pharmacotherapy 12:18, pages 2817-2831.
Read now
Read now
Articles from other publishers (24)
Tian Shen, Xingyu Li, Lei Chen, Zimu Chen, Tingting Tan, Tiantian Hua, Bingwei Chen, Yonggui Yuan, Zhijun Zhang, Liz Kuney & Zhi Xu. (2020) The relationship of tryptophan hydroxylase-2 methylation to early-life stress and its impact on short-term antidepressant treatment response. Journal of Affective Disorders 276, pages 850-858.
Crossref
Crossref
Chemin Lin, Helmet T. Karim, Marta Pecina, Howard J. Aizenstein, Eric J. Lenze, Daniel M. Blumberger, Benoit H. Mulsant, Evan D. Kharasch, Charles F. Reynolds III & Jordan F. Karp. (2019) Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression. NeuroImage: Clinical 21, pages 101679.
Crossref
Crossref
Tetsu Tomita, Yasushi Sato, Taku Nakagami, Shoko Tsuchimine, Ayako Kaneda, Sunao Kaneko, Kazuhiko Nakamura & Norio Yasui-Furukori. (2016) Items of the Montgomery-Åsberg Depression Rating Scale Associated With Response to Paroxetine Treatment in Patients With Major Depressive Disorder. Clinical Neuropharmacology 39:3, pages 135-139.
Crossref
Crossref
Mark Weiser & George Garibaldi. (2015) Quantifying motivational deficits and apathy: A review of the literature. European Neuropsychopharmacology 25:8, pages 1060-1081.
Crossref
Crossref
Catherine Cameron, Jeff Habert, Leena Anand & Melissa Furtado. (2014) Optimizing the management of depression: primary care experience. Psychiatry Research 220, pages S45-S57.
Crossref
Crossref
Paolo Olgiati, Emanuele Bajo & Alessandro Serretti. (2014) Benefit of slow titration of paroxetine to treat depression in the elderly. Human Psychopharmacology: Clinical and Experimental 29:6, pages 544-551.
Crossref
Crossref
Murat Altin, Eiji Harada, Alexander Schacht, Lovisa Berggren, Daniel Walker & Hector Dueñas. (2014) Does Early Improvement in Anxiety Symptoms in Patients with Major Depressive Disorder Affect Remission Rates? A Post-Hoc Analysis of Pooled Duloxetine Clinic Trials. Open Journal of Depression 03:03, pages 112-123.
Crossref
Crossref
Angelo Alonzo, Grace Chan, Donel Martin, Philip B. Mitchell & Colleen Loo. (2013) Transcranial direct current stimulation (tDCS) for depression: Analysis of response using a three-factor structure of the Montgomery–Åsberg depression rating scale. Journal of Affective Disorders 150:1, pages 91-95.
Crossref
Crossref
P. Gorwood, F. Bayle, G. Vaiva, P. Courtet, E. Corruble & P.-M. Llorca. (2020) Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis. European Psychiatry 28:6, pages 362-371.
Crossref
Crossref
Seung-Hwan SungSeon-Cheol ParkKyu-Man HanEun-Soo WonHwa-Young LeeJae-Woo KooJong-Woo PaikKyung-Min LeeHong Jin JeonMoon-Soo LeeSe-Hoon ShimYoung-Hoon KoKang-Joon LeeChangsu HanByung-Joo HamJoonho ChoiTae-Yeon HwangKang-Seob OhYong-Chon ParkMin-Soo LeeSang-Woo Hahn. (2013) Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (II) : Antidepressant Efficacy Compared with Placebo, Difference in Efficacy of Antidepressants, and Appropriate Time of Efficacy Judgment in Antidepressant Therapy. Journal of Korean Neuropsychiatric Association 52:5, pages 372.
Crossref
Crossref
Szilvia Vas, Zita Kátai, Diána Kostyalik, Dorottya Pap, Eszter Molnár, Péter Petschner, Lajos Kalmár & György Bagdy. (2012) Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment. Journal of Neural Transmission 120:1, pages 169-176.
Crossref
Crossref
Siegfried Kasper, Bjarke Ebert, Klaus Larsen & Brigitte Tonnoir. (2011) Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder. The International Journal of Neuropsychopharmacology 15:06, pages 715-725.
Crossref
Crossref
Anjana Bose, Joyce Tsai & Dayong Li. (2012) Early Non-Response in Patients with Severe Depression. Clinical Drug Investigation 32:6, pages 373-385.
Crossref
Crossref
H.-J. Möller, I. Bitter, J. Bobes, K. Fountoulakis, C. Höschl & S. Kasper. (2020) Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. European Psychiatry 27:2, pages 114-128.
Crossref
Crossref
Huailing Zhong, Nasser Haddjeri & Connie Sánchez. (2011) Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action. Psychopharmacology 219:1, pages 1-13.
Crossref
Crossref
R. J. de Knegt, G. Bezemer, A. R. Van Gool, J. P. H. Drenth, B. E. Hansen, H. A. Droogleever Fortuyn, C. J. Weegink, M. W. Hengeveld & H. L. A. Janssen. (2011) Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Alimentary Pharmacology & Therapeutics 34:11-12, pages 1306-1317.
Crossref
Crossref
A. G. Wade, G. M. Crawford, C. B. Nemeroff, A. F. Schatzberg, T. Schlaepfer, A. McConnachie, L. Haazen & E. Buntinx. (2011)
Citalopram plus low-dose pipamperone
versus
citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response
. Psychological Medicine 41:10, pages 2089-2097.
Crossref
Crossref
Brian Leonard & David Taylor. (2010) Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression. Journal of Psychopharmacology 24:8, pages 1143-1152.
Crossref
Crossref
Raymond W. Lam, Sidney H. Kennedy, Sophie Grigoriadis, Roger S. McIntyre, Roumen Milev, Rajamannar Ramasubbu, Sagar V. Parikh, Scott B. Patten & Arun V. Ravindran. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.. Journal of Affective Disorders 117, pages S26-S43.
Crossref
Crossref
Alexander Friedman, Avia Merenlender, Elad Lax, Mordechay Rosenstein, Nachum Lubin & Gal Yadid. (2009) Early Prediction of the Effectiveness of Antidepressants: Inputs from an Animal Model. Journal of Molecular Neuroscience 39:1-2, pages 256-261.
Crossref
Crossref
Dominick Esposito, Peter Wahl, Gregory Daniel, Michael A. Stoto, M. Haim Erder & Thomas W. Croghan. (2009) Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States. Clinical Therapeutics 31:3, pages 644-656.
Crossref
Crossref
A.G. Wade, T.E. Schlaepfer, H.F. Andersen & C.D. Kilts. (2009) Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). Journal of Psychiatric Research 43:5, pages 568-575.
Crossref
Crossref
P. Van Dijck. (2007) Escitalopram, un développement clinique complet. L'Encéphale 33, pages 134-139.
Crossref
Crossref
David S Baldwin, Elin Heldbo Reines, Christina Guiton & Emmanuelle Weiller. (2016) Escitalopram Therapy for Major Depression and Anxiety Disorders. Annals of Pharmacotherapy 41:10, pages 1583-1592.
Crossref
Crossref